Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin®) induces high response rates and durable remissions in patients with relapsed or refractory B-cell non hodgkin's lymphoma (NHL) Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Murray, JL
  • Witzig, TE
  • Molina, A
  • Gordon, L
  • Emmanouilides, C
  • Vo, K
  • Flinn, IW
  • Czuczman, Mark
  • Saville, W
  • Wiseman, G
  • White, CA